Gilead Sciences: Exec Insiders and Funds Cashing Stock in Q3

Read Trending Stories

Today's Trending Stocks

Click a Company to Research Now:

Insiders are generally long-term investors due to restriction in making short-term profits. In contrast, wealth management institutions always have short-term investment. Wall St. Watchdog reveals information regarding the insiders and institutions which recently decreased stock shares of Gilead Sciences Inc. (NASDAQ:GILD).

SEC data indicate these insiders have sold Gilead Sciences Inc.’s stock since 06/30/2011:

  • Martin John C: act as Chairman and CEO. On 07/01/2011, sold 92,320 shares, worth $3,855,300.
  • Martin John C: act as Chairman and CEO. On 08/01/2011, sold 92,320 shares, worth $3,851,600.
  • Martin John C: act as Chairman and CEO. On 11/01/2011, sold 92,320 shares, worth $3,789,700.
  • Martin John C: act as Chairman and CEO. On 09/01/2011, sold 92,320 shares, worth $3,699,300.
  • Martin John C: act as Chairman and CEO. On 10/10/2011, sold 92,320 shares, worth $3,692,800.

SEC data indicate that these institutions significantly reduced their stock shares of Gilead Sciences Inc. in Q3 2011:

  • MAVERICK CAPITAL LTD: On 06/30/2011, held 3,278,333 shares, worth $135,755,770. On 09/30/2011, held 0 shares.
  • RENAISSANCE GROUP LLC: On 06/30/2011, held 1,267,968 shares, worth $52,506,555. On 09/30/2011, held 0 shares.
  • PARTNER FUND MANAGEMENT, L.P.: On 06/30/2011, held 1,210,774 shares, worth $50,138,151. On 09/30/2011, held 0 shares.
  • HEALTHCOR GROUP, LLC: On 06/30/2011, held 1,000,000 shares, worth $41,410,000. On 09/30/2011, held 0 shares.
  • HEALTHCOR MANAGEMENT, L.P.: On 06/30/2011, held 1,000,000 shares, worth $41,410,000. On 09/30/2011, held 0 shares.

About the company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Competitors to Watch: Roche Holding Ltd. (RHHBY), GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol Myers Squibb Co. (NYSE:BMY), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Trimeris, Inc. (NASDAQ:TRMS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Hemispherx BioPharma, Inc (AMEX:HEB).

(Note: Data regarding Gilead Sciences Inc.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!

Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.

Click here now for your FREE trial to our acclaimed flagship newsletter:

Learn More

Advertisement:
Improve your Investing Portfolio with Wall St Cheat Sheet Premium

Intelligent Investing

Wall St. Cheat Sheet Premium

Tired of wasting time and money sifting through the noise on TV, websites, and Twitter? Get winning stock picks now.

Gold & Silver Premium

Join Chicago Mercantile Exchange commentator Eric McWhinnie as he covers Gold & Silver for you.

Commodities Premium

Commodities are heating up. This is an investment newsletter you'll need to win in the bull market.

Wall St. Cheat Sheet has been featured in these fine media outlets: